Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aaron Long

Clinical Trials Coordinator

Aaron originally completed his BSc in 2014 at the University of Derby in Sports Science, and has been working in healthcare since 2015. Initially he worked as a Research Practitioner at the University of Coventry where he worked on the SMARTChip study, the study was investigating the validation of purine biosensor in detecting acute ischaemia.

He came to the University of Oxford in 2016 where he worked at the Nuffield Department of Primary Care and Health Sciences as a Clinical Trials Facilitator. As part of the Cardiovascular and Renal Theme he worked closely with Professor Richard Hobbs managing the BARACK-D Trial, which was investigating the use of Spironolactone in patients with Chronic Kidney Disease.

In 2019 he took a small stint out of the academic world to work for Phlexglobal Limited to provide software and leading expert clinical services to pharmaceutical companies. He mainly worked on Pfizer lead trials providing oversight of all electronic Trial Master File (TMF) management activities for assigned projects from award to final transfer. He drove and oversaw successful completion of all TMF scoped deliverable including TMF Plan development, TMF set-up and monitoring documents submissions/publishing and processing.

Aaron joined the Department in 2020 as a Clinical Trial Coordinator, he works closely with Professor Laurent Servais within the Specialised Translational Research Oxford Neuromuscular Group (STRONG) within the MDUK Oxford Neuromuscular Centre. The MDUK Oxford Neuromuscular Centre is a partnership between Muscular Dystrophy UK and the University of Oxford. It was established in January 2019 and aims to drive forward the development of novel experimental therapies and increase national clinical trial capacity in neuromuscular diseases.